Cannara Biotech Inc. is seeing a significant rise in its stock price, which reflects positive investor sentiment.
Cannara Biotech Inc. (LOVE.TO) shares are up 1.82% today, reaching CA$2.24. This increase comes as the company makes strategic moves to improve its financial standing and operational capabilities.
Advertisement
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$210.41M
P/E
19.4x
52W high
$2.20
52W low
$1.55
1W change
+10.55%
Beta
0.36
Analyst Price Targets
Based on analyst covering LOVE · as of Sep 17, 2026
Wall Street analysts forecast LOVE stock price to fall 77.0% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
-77.0% Upside
Current Price
C$14.70
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
18.5%
Annualized
90-Day Vol
30.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.63
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.33 | C$2.19 – C$2.49 |
| 60 trading days | C$2.48 | C$2.26 – C$2.71 |
| 90 trading days | C$2.63 | C$2.35 – C$2.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may find Cannara's recent financial actions and management changes reassuring as the company aims for sustained growth in the competitive cannabis sector.
Cannara Biotech's Market Cap Reaches CA$210.4 Million
With a market cap of CA$210.4 million, Cannara Biotech's financial health is bolstered by its recent credit facility expansion and management changes.
Bull case
Cannara's recent expansion of its credit facility to $80 million gives the company more liquidity, which can support growth initiatives and operational improvements.
Bear case
Despite the positive trend, Cannara Biotech operates in a volatile market. Any missteps in execution could hurt investor confidence and affect stock performance.
Strategic Financial Moves
Advertisement
Cannara's announcement of an expanded $80 million credit facility with BMO and TD Bank boosts its financial flexibility. This is crucial for supporting ongoing operations and potential growth initiatives, positioning the company well in the competitive cannabis market.
Management Enhancements
The appointment of Nicholas Fozard as Chief Financial Officer is a significant step for Cannara. Strong leadership is essential for navigating the complexities of the cannabis industry, and investors may see this as a positive sign of the company's commitment to good governance.
Market Performance and Outlook
With a market cap of CA$210.4 million and a recent stock price increase, Cannara Biotech is gaining traction among investors. However, the volatility in the cannabis sector requires cautious optimism as the company continues to implement its growth strategies.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
